Harrow (HROW) Cash & Current Investments (2010 - 2026)
Harrow (HROW) posted Cash & Current Investments of $83.9 million for Q2 2026, down 11.36% on a QoQ basis from $94.6 million in Q1 2026, and up 58.39% year-over-year from $53.0 million in Q2 2025.
Analysis
Harrow (HROW) Cash & Current Investments (2010 - 2026) Analysis & Trends
Harrow has reported Cash & Current Investments for 17 years, with the latest figure at $83.9 million in Q2 2026.
- On a quarterly basis, Cash & Current Investments rose 58.39% year-over-year to $83.9 million in Q2 2026; TTM through Jun 2026 was $83.9 million, a 58.39% increase from a year earlier, with the FY2025 full-year figure at $72.9 million, up 54.35% from the prior year.
- Cash & Current Investments was $83.9 million for Q2 2026 at Harrow, down from $94.6 million in the prior quarter.
- The five-year high for Cash & Current Investments was $101.9 million in Q4 2022, with the low at $26.9 million in Q1 2023.
- Average Cash & Current Investments over 5 years is $65.5 million, with a median of $71.8 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2023: Cash & Current Investments surged 677.83% in 2022, then sank 46.87% in 2023.
- Over 5 years, Cash & Current Investments stood at $101.9 million in 2022, then slipped by 18.74% to $82.8 million in 2023, then plunged by 42.91% to $47.2 million in 2024, then soared by 54.35% to $72.9 million in 2025, then increased by 15.03% to $83.9 million in 2026.
- The last three Cash & Current Investments figures came in at $83.9 million (Q2 2026), $94.6 million (Q1 2026), and $72.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.95 Bn | 625.20 Bn | 17.26 Bn | 20.76 Bn |
| 2 | AbbVie | 441.39 Bn | 434.82 Bn | 12.70 Bn | 6.57 Bn |
| 3 | Merck | 366.72 Bn | 359.58 Bn | 12.21 Bn | 7.14 Bn |
| 4 | Novartis Ag | 266.68 Bn | 258.99 Bn | 11.24 Bn | 7.69 Bn |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 11.70 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 7.38 Bn |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.50 Bn | 20.96 Bn | 1.57 Bn | 4.54 Bn |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 2.66 Bn |
| 10 | Harrow | 1.40 Bn | 1.32 Bn | 50.36 Mn | 83.89 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 83.89 Mn |
| Mar 31, 2026 | 94.64 Mn |
| Dec 31, 2025 | 72.93 Mn |
| Sep 30, 2025 | 74.29 Mn |
| Jun 30, 2025 | 52.96 Mn |
| Mar 31, 2025 | 66.73 Mn |
| Dec 31, 2024 | 47.25 Mn |
| Sep 30, 2024 | 72.60 Mn |
| Jun 30, 2024 | 70.97 Mn |
| Mar 31, 2024 | 75.97 Mn |
| Dec 31, 2023 | 82.77 Mn |
| Sep 30, 2023 | 73.88 Mn |
| Jun 30, 2023 | 29.67 Mn |
| Mar 31, 2023 | 26.88 Mn |
| Dec 31, 2022 | 101.86 Mn |
| Sep 30, 2022 | 49.12 Mn |
| Jun 30, 2022 | 51.63 Mn |
| Mar 31, 2022 | 50.59 Mn |
| Dec 31, 2021 | 50.67 Mn |
| Sep 30, 2021 | 67.85 Mn |